Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort

Johan Pallud; Étienne Audureau; G. Noël; Robert Corns; Emmanuèle Lechapt; J. Duntze; Vladislav Pavlov; Jacques Guyotat; Phong Dam Hieu; Pierre‐Jean Le Reste; Thierry Faillot; Claude‐Fabien Litré; Nicolas Desse; Antoine Petit; Évelyne Emery; Jimmy Voirin; Johann Peltier; François Caire; Jean‐Rodolphe Vignes; Jean‐Luc Barat; Olivier Langlois; Edouard Dezamis; Eduardo Párraga; Marc Zanello; E. Nader; Michel Lefranc; Luc Bauchet; Bertrand Devaux; Philippe Meneï; Philippe Métellus

doi:10.1093/neuonc/nov126

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Carmustine wafer implantation during surgical resection followed by the standard chemoradiation protocol for newly diagnosed glioblastoma in adults resulted in a significant progression-free survival benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pallud et al. (2015) studied this question.

synapsesocial.com/papers/69de91b1726bee048db0c87c https://doi.org/10.1093/neuonc/nov126

View Full Paper

Ask AI

Bookmark

Share

Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort

Ask about this paper

Abstract

Discussion

Cite This Study

Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading